XtalPi and Pierre Fabre have entered an AI-led drug discovery partnership targeting complex oncology research, utilizing XtalPi's robotics platform to accelerate the development of new small-molecule candidates.
XtalPi (2228.HK) announces an AI-driven drug discovery collaboration with Pierre Fabre covering oncology and possibly dermatology and rare diseases. The deal includes an upfront payment, milestone payments and downstream profit sharing, but the financial terms are not disclosed, so no quantified value can be weighed against the partnership's validation of its AI/robotics platform.
XtalPi (2228.HK) and Les Laboratoires Pierre Fabre announced a collaboration on 9 November 2026 to identify clinical candidates for oncology, dermatology, and rare diseases. XtalPi will deploy its AI and robotics platform to design small-molecule treatments, while Pierre Fabre manages clinical development and commercialization. The agreement includes an upfront payment, milestone payments, and profit sharing, though specific financial terms remain undisclosed.
The article does not disclose the precise financial terms; it only mentions an upfront payment, milestone payments and a share of downstream profits.
XtalPi will use its AI and robotics platform to design small-molecule drug candidates against undisclosed targets in oncology and potentially dermatology and rare diseases, while Pierre Fabre handles clinical development and commercialization.